### Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden 0.5 hours per response..

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	es)														
1. Name and Address of Reporting Person *- BIZZARI JEAN-PIERRE				2. Issuer Name and Ticker or Trading Symbol PIERIS PHARMACEUTICALS, INC. [PIRS]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner						
(Last) (First) (Middle) C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR				3. Date of Earliest Transaction (Month/Day/Year) 02/16/2016								re title below)		er (specify below	)	
BOSTON, MA 02109				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City) (State) (Zip)			(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
1.Title of S (Instr. 3)	Security		Date (Month/Day/Year)	2A. Deen Execution any (Month/I	n Date	e, if Co		8) (1	. Securities Ac A) or Disposed (nstr. 3, 4 and 5	of (D)	Owner Trans (Instr		ving Report	I I c	Ownership Form: B Direct (D) O	Nature f Indirect eneficial ewnership nstr. 4)
								contair form d	es who responed in this for isplays a cur osed of, or Beronvertible secu	rm are rently reficial	not ovalid	required OMB c	d to respo	nd unless th		74 (9-02)
1. Title of Derivative Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	f Transaction Code r) (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		Amo Unde Secu	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisabl	Expiration Date	Title		Amount or Number of Shares				
Stock Option (right to buy)	\$ 1.59	02/16/2016		A	2	20,000		(1)	02/16/2020	1	nmon	20,000	\$ 0	20,000	D	

# **Reporting Owners**

Reporting Owner Name / Address	Relationships						
reporting 6 wher readers	Director	10% Owner	Officer	Other			
BIZZARI JEAN-PIERRE C/O PIERIS PHARMACEUTICALS, INC. 255 STATE STREET, 9TH FLOOR BOSTON, MA 02109	X						

# **Signatures**

/s/ Marc D. Mantell, Attorney-in-fact	02/18/2016		
**Signature of Reporting Person	Date		

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The stock option will vest in four equal installments on each of March 31, June 30, September 30, and December 31, 2016.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.